Article ID Journal Published Year Pages File Type
8277343 Journal of the Neurological Sciences 2014 5 Pages PDF
Abstract
These results suggest that JGK-263, an oral GSK-3β inhibitor, is promising as a novel therapeutic agent for ALS. Still, further biochemical studies on the underlying mechanisms and safety of JGK-263 are necessary.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Ageing
Authors
, , , , , , , , , , , ,